






FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E





FIG. 1F



Ashcroft's Score

4

3

2

1

0

####

3.2

1.8

0.8

FIG. 2C

% Collagen Proportionate Area (CPA)

30

20

10

0

####


25

15

1


FIG. 2D

3/24



Normal Control

FIG. 3A




Bleomycin (BLM) + Vehicle

FIG. 3B




BLM + Pirfenidone 100mg/kg (T)

FIG. 3C




Compound 1, 10mpk (P)

FIG. 3D




Compound 1, 30mpk (P)

FIG. 3E



Compound 1, 100mpk (P)

FIG. 3F











Compound 1, 100mpk (P)

FIG. 3G


4/24

Naive
LPS control
Dexamethasone 5 mpk
Compound 3, 30 mpk





6/24



Effects of Compound 3 on IL-8 Induced




FIG. 7A




FIG. 7B

Effects of Compound 3 on fMLP Induced Chemotaxis




FIG. 7C




FIG. 7D

8/24




FIG. 8A

9/24

Disease Parameters Evaluated on Day 8

Sacrifice




FIG. 8B




FIG. 8C




FIG. 8D

10/24




FIG. 9B

FIG. 9A

11/24




FIG. 10B

FIG. 10A

12/24




FIG. 11A




FIG. 11B




FIG. 11C

13/24

Dermatitis Severity scores in MC-903 animal model




FIG. 12A

Pictorial representation of mouse back skin post MC-903 application in different mice groups




FIG. 12B

Compound 2 robustly reduces epidermal thickness, a key sign of AD lesions, in the MC903-induced model of Atopic Dermatitis along with neutrophil infiltration




FIG. 12C

Graphical representation of epidermal thickness and tissue Lipocalin-2 (NGAL)




FIG. 12D

16/24

Compound 2 shows reduced dose-dependent immune cell infiltration as measured by histopathology concurrent with observed efficacy




FIG. 12E

Compound 2 significantly reduces NGAL levels demonstrating a clear mechanistic link




FIG. 12F

17/24

Compound 2 reduces early barrier alarmins in skin that are elevated in skin lesions of AD patients




FIG. 12G

Compound 2 impacts tissue cytokine expression directly involved in the progression of atopic dermatitis pathophysiology




FIG. 12H

18/24

Compound 2 decreases IL-31 expression, a cytokine directly linked to pruritus in AD




FIG. 12I

Compound 2 showed dose dependent decrease in dermatitis severity scores when compared with DNFB vehicle control




FIG. 13A

19/24

Compound 2 reduces immune cell infiltration and ameliorates DNFB-induced histopathology




FIG. 13B

Compound 2 significantly reduces epidermal thickness and histopathology score




FIG. 13C

20/24

Compound 2 impacts IL-4 expression, a key cytokine directly involved in the pathogenic cascade of atopic dermatitis




FIG. 13D

Compound 2 reduces itch comparably to current first line therapy for AD




FIG. 13E

21/24

Compound 2 significantly reduces dermatitis erythema & dermatitis scaling scores in the MC-903 model of atopic dermatitis




FIG. 14

22/24

Compound 2 significantly reduces dermatitis severity scores on-par with oral JAK-i in the MC903 AD model




FIG. 15

23/24

Compound 2 significantly reduces dermatitis severity scores as low as 0.1 mg/kg in the MC903 model of AD




FIG. 16




FIG. 17